

## 9<sup>th</sup> ECTRIMS FOCUSED WORKSHOP

### *“Autologous haematopoietic stem cell transplantation for treatment of MS and related diseases” Virtual meeting 10-11 March 2022*

**Aims:**

1. To produce practical guidance for clinicians, patients and healthcare payers from a process involving review of evidence and expert consensus recommendations with the support of the leading sub-specialist organisation.
2. To provide a forum for the professional/scientific development and update of key opinion leaders in the neurological and haematological communities across Europe that could subsequently share their knowledge in their respective European countries.
3. To publish articles (1-2 papers) with high potential to influence and improve clinical practice and healthcare policy development.

**Format:** Online (part pre-recorded, part live) meeting. Talks will be pre-recorded and sent to session chairs one week before the Day 1 live Parallel Sessions. During the live sessions, each session’s pre-recorded presentations will be delivered and there will be ample time for discussion between all presenters, other discussants and chairs. There will be 4 sessions in two parallel streams.

**Structure:**

Day 1: Plenary session 1; Parallel sessions 1 and 2

Day 2: Parallel sessions 3 and 4; and Plenary session 2

Parallel sessions streams:

Neurological stream: Sessions 1 and 3

Haematological stream: Sessions 2 and 4

**Organizing committee:** Paolo Muraro, Basil Sharrack, Joachim Burman, John Snowden, Raffaella Greco, Ellen Iacobaeus, Matilde Inglese, Bruno Stankoff

## Day 1 - Thursday, 10<sup>th</sup> March 2022

### 14.00 – 15.10 **Plenary Session 1**

Chairs: B Stankoff (Paris, FR), P Muraro (London, UK), R Greco (Milano, IT)

#### 14.00 **Welcome, Objectives and structure of WS**

B Stankoff (Paris, FR), P Muraro (London, UK), R Greco (Milano, IT)

#### 14.10 **Immunological rationale and mechanisms of HSCT: how evidence from HSCT treatment trials can provide insights about the pathogenesis of MS?**

R Martin (Zurich, CH)

#### 14.40 **HSCT clinical evidence: large cohort studies, RCTs and meta-analyses**

M Inglese (Genoa, IT)

### 15.10 – 15.20 **Short Break**

### 15.20 – 17.35 **Parallel Session 1: Neurological indications (within MS and related diseases) and optimal patient selection**

Chairs: M Tintoré (Barcelona, ES) and B Sharrack (Sheffield, UK)

#### 15.20 **Clinical experience and ongoing RCT in RRMS**

L Bo (Bergen, NO)

#### 15.35 **When should HSCT be considered in the sequence of possible disease modifying therapies?**

MP Amato (Firenze, IT)

#### 15.50 **Is HSCT an option in treatment-naïve people with MS?**

J Burman (Uppsala, SE)

#### 16.05 **HSCT outcomes in progressive MS: is there evidence of benefit and acceptable risk?**

A Mariottini (Firenze, IT)

#### 16.20 **AHSCT for treatment of NMOSD**

L Moiola (Milano, IT)

#### 16.35 **Round table discussion** with discussants (1 hour)

### 15.20 – 17.20 **Parallel Session 2: Haematological evaluation (including fertility management) and transplant protocol**

Chairs: R Saccardi (Firenze, IT) and M Kazmi (London, UK)

- 15.20      **Pre-transplant assessments and screening for comorbidities in HSCT candidates**  
M Kazmi (London, UK)
- 15.35      **Fertility**  
M Gaughan (Dublin, IE)
- 15.50      **Conditioning regimens in patients with multiple sclerosis: BEAM/ATG versus Cyclophosphamide/ATG**  
R Saccardi (Firenze, IT)
- 16.05      **Transplant protocols and safety/tolerability in NMOSD**  
R Greco (Milano, IT)
- 16.20      **Round table discussion** with discussants (1 hour)

## **Day 2 - Friday, 11<sup>th</sup> March 2022**

- 14.00 – 16.00**    **Parallel Session 3: Post-HSCT management; including neurological and MRI f/u, neuro-rehabilitation**  
Chairs: E Iacobaeus (Stockholm, SE) and GL Mancardi (Genova, IT)
- 14.00      **Clinical monitoring of MS course after HSCT**  
C Heesen (Hamburg, DE)
- 14.15      **MRI monitoring of HSCT**  
O Ciccarelli (London, UK)
- 14.30      **Management of relapses and MS reactivation, including reintroduction of DMTs**  
G Boffa (Genova, IT)
- 14.45      **Round table discussion** with discussants (1 hour)
- 14.00 – 16.15**    **Parallel Session 4: Post-HSCT management; including early and late effects, virological and immune monitoring, vaccinations**  
Chairs: R Greco (Milano, IT) and J Snowden (Sheffield, UK)
- 14.00      **Vaccination programme after HSCT**  
P Ljungman (Stockholm, SE)
- 14.15      **CMV/EBV Reactivations**  
V Mehra (London, UK)

- 14.30           **Immune monitoring after autologous HSCT**  
T Alexander (Berlin, DE)
- 14.45           **Secondary autoimmunity after autologous HSCT in MS**  
J Burman (Uppsala, SE)
- 15.00           **Late complications after autologous HSCT**  
K Kirgizov (Moscow, RU)
- 15.15           **Round table discussion** with discussants (1 hour)
- 16.00 – 16.30   Short break**
- 16.30 – 17.50   Plenary session 2 - Wrap up summaries**
- Chairs from Parallel Sessions 1 - 4 will present brief summaries of the highlights and “take home messages” from their sessions.
- 16.30           **Wrap-up of session 1 and 3 – Neurological stream**  
M Tintoré (Barcelona, ES) and B Sharrack (Sheffiled, UK)  
E Iacobaeus (Stockholm, SE) and GL Mancardi (Genova, IT)
- 17.00           **Wrap-up of session 2 and 4: Haematological stream**  
R Saccardi (Firenze, IT) and M Kazmi (London, UK)  
R Greco (Milano, IT) and J Snowden (Sheffiled, UK)
- 17.30           **Consensus summary: agreed output of the meeting**  
P Muraro (London, UK) and B Sharrack (Sheffield, UK)
- 17.45           **Concluding remarks from ECTRIMS**  
E Iacobaeus (Stockholm, SE), T Derfuss (Basel, CH) and B Stankoff (Paris, FR)
- 17.50           End of Focused Workshop**